Loading
A phase 1/2 trial of Fulvestrant, Ribociclib, Palbociclib, Exemestane, Tamoxifen and Abemaciclib in advanced solid tumours, run by Eli Lilly and Company, now recruiting.
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05768139 by Eli Lilly and Company, with 880 participants planned, started 2023-04-17 and due to reach its primary completion in 2030-07. Interventions recorded: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole and Anastrozole.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Exemestane, Tamoxifen, Eli Lilly (incl. Loxo), UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Abemaciclib, Tamoxifen, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Palbociclib, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, Fulvestrant, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/